Last reviewed · How we verify
TS-1, oxaliplatin
TS-1 is a combination chemotherapy regimen that inhibits thymidylate synthase and DNA synthesis, while oxaliplatin is a platinum-based agent that forms DNA crosslinks to kill cancer cells.
TS-1 is a combination chemotherapy regimen that inhibits thymidylate synthase and DNA synthesis, while oxaliplatin is a platinum-based agent that forms DNA crosslinks to kill cancer cells. Used for Gastric cancer (advanced or metastatic), Colorectal cancer.
At a glance
| Generic name | TS-1, oxaliplatin |
|---|---|
| Sponsor | Samsung Medical Center |
| Drug class | Fluoropyrimidine + platinum-based chemotherapy combination |
| Target | Thymidylate synthase; DNA (platinum crosslinking) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
TS-1 (tegafur/gimeracil/oteracil potassium) is an oral fluoropyrimidine prodrug that inhibits thymidylate synthase, disrupting nucleotide synthesis and DNA replication. Oxaliplatin is a third-generation platinum compound that forms interstrand and intrastrand DNA crosslinks, preventing DNA unwinding and replication. Together, they provide synergistic cytotoxic effects against rapidly dividing cancer cells.
Approved indications
- Gastric cancer (advanced or metastatic)
- Colorectal cancer
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
- Nausea and vomiting
- Diarrhea
- Peripheral neuropathy
- Hand-foot syndrome
Key clinical trials
- Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659) (PHASE2)
- Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction Cancer (PHASE2)
- Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer (PHASE2)
- S-1/Oxaliplatin for High Risk Patients Who Underwent Gastrectomy (PHASE2)
- Phase III Randomized Trial of Adjuvant Chemotherapy With S-1 vs S-1/Oxaliplatin ± Radiotherapy for Completely Resected Gastric Adenocarcinoma : The ARTIST II Trial (PHASE3)
- A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared With Chemoradiotherapy in Gastric Adenocarcinoma (PHASE2)
- Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer (PHASE2)
- S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |